As a result, the amount of interferon (IFN)‐γ was significantly improved following anti‐NKG2A antibody treatment compared with the isotype (Figure S15), indicating that targeting the HLA‐E‐KLRC1 signalling might be a novel clinical therapeutic opportunity in GC. The gene discussed is KLRC1; the disease is gastric cancer.